Laila Seouif ends hunger strike amid concerns for her deteriorating health
Soueif's decision came a few days after her family and rights figures pleaded for her to take medical advice and end her strike, following her brief readmission to hospital in London that her daughters said was due to a deterioration in her health.
Mona Seif's latest statement stressed that Soueif is still in critical condition, explaining that while doctors have started a refeeding plan, several risks connected with prolonged malnutrition still need to be considered, including refeeding syndrome.
Doctors have warned that the prolonged hunger strike could cause permanent damage that may extend to vital organs, while Soueif received a medical recommendation during her hospital admission last week to end her strike, at least temporarily.
After her admission to hospital, Mona issued a plea for her mother to end the strike, fearing for her life. She called on those close to her mother to intervene and help convince her to end the strike to save her life and prevent the family from enduring yet another loss.
The plea was followed by other calls that were made for Soueif to end her hunger strike, from family friends and public figures, including Mohamed al-Baqer, Abd El Fattah's former lawyer. In his statement, Baqer urged Soueif to end the strike, not because her efforts were futile, but out of the 'horror of losing' her.
Soueif began her hunger strike on September 30 to protest Egyptian authorities' refusal to release Abd El Fattah at the end of his five-year sentence on false news charges, according to a statement made by the family at the time.
Through extreme weight loss and several hospital admissions, Soueif has remained adamant that she will continue her strike as a last resort to pressure authorities in both Egypt and the United Kingdom to intervene to release Abd El Fattah. She and her son hold nationality in both countries.
Abd El Fattah has been imprisoned since 2019, although he was convicted on false news charges and ordered to serve no longer than five years.
Authorities refuse to count the two years he spent in remand detention toward his sentence. Amnesty International has cautioned that officials may find grounds to extend his detention beyond 2027, while a group of United Nations experts has concluded that the writer is now being held arbitrarily.
Sanaa Seif stressed in her statement that Abd El Fattah is still committed to the partial hunger strike he began in prison on March 1.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily News Egypt
7 hours ago
- Daily News Egypt
Egyptian Drug Authority discusses plans for joint pharmaceutical plant in Zambia
Ali El-Ghamrawi, head of the Egyptian Drug Authority, held talks with a joint delegation from Egyptian firm Wadi El-Nile and Zambian developer Pendulum Estates Ltd as part of Egypt's strategy to expand into African markets and strengthen international pharmaceutical partnerships. Discussions centred on plans to establish a joint drug manufacturing plant in Zambia. The initiative aligns with Egypt's broader vision to deepen industrial integration across Africa, transfer expertise and technology, boost regional production capacity, encourage pharmaceutical investment, and enhance regulatory cooperation with African counterparts. It also aims to reinforce Egypt's position as a regional pharmaceutical hub and contribute to securing medicine supplies across the continent. During the meeting, El-Ghamrawi highlighted that localising pharmaceutical production in African countries remains a strategic priority for the Authority. He described the African market as a key target for Egyptian pharmaceutical expansion, both to improve access to essential medicines and support local industry development. Mohamed Dabour, Chairperson of Wadi El-Nile, emphasised the importance of the partnership with the Zambian side, describing the project as a major milestone in the company's plans to expand across Africa and help localise pharmaceutical production on a continental scale. John Zulu, Chairperson of Pendulum Estates Ltd, welcomed the cooperation with Egypt and described the partnership as transformative for Zambia's healthcare system, enabling the domestic production of high-quality medicines to meet local demand. The delegation praised the Drug Authority's strategic leadership and its advanced regulatory and technical expertise, which they said has helped elevate Egypt's pharmaceutical sector both regionally and internationally. They noted that collaboration with the Authority would provide vital technical support, advisory services, and regulatory facilitation needed for the success of the proposed joint plant in Zambia — ultimately enhancing access to quality medicines and supporting health security across Africa. The partnership reflects the Drug Authority's commitment to fostering deeper cooperation with African nations and backing pharmaceutical investments that promote industry growth and deliver tangible health benefits across the continent.
Daily News Egypt
2 days ago
- Daily News Egypt
Sandoz Egypt introduces OMNITROPE 15mg biosimilar growth hormone for the treatment of short stature
Sandoz the global leader in generic and biosimilar medicines, announced the introduction of its 15mg/1.5ml concentration of the OMNITROPE biosimilar growth hormone for the treatment of short stature to the Egyptian market, as part of its ongoing efforts to support Egypt's Vision 2030. Local healthcare authorities remain committed to addressing various health challenges to enhance public health for current and future generations, and help build a healthier, more productive workforce. Research conducted at the Suez Canal University endocrinology outpatient clinic in Ismailia City, Egypt and released in 2024, underscored the importance of short stature treatment, with findings indicating that treatment with growth hormone significantly improved physical, social, psychological, and environmental quality of life¹. 'In children and adolescents, growth hormone is used to treat growth disturbance due to insufficient secretion of growth hormone, associated with Turner syndrome, with chronic renal insufficiency, in short children/adolescents born small for gestational age, or associated with Prader-Willi syndrome (PWS). The biosynthetic/synthetic hormone is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone (GH)² ³,' Dr. Mona Salem, Professor of Paediatric Endocrinology at Ain Shams University and President of the Egyptian Society of Paediatric Endocrinology & Diabetes, said. 'Short stature is diagnosed in children or adolescents who are well below the average height for their age and gender, which may be due to genetic factors or underlying health conditions⁴ ⁵. Studies show that short stature prevalence varies geographically, with a genetic predisposition, as well as nutritional and environmental factors, playing an important role⁶,' Dr Salem added. A cross-sectional study conducted between January 2018 and January 2020 involving 33,150 Egyptian children aged 6 to 11 showed that 17% of the sample had short stature, with 40.8% attributed to familial factors and 24.2% to constitutional causes⁷. 'As noted, short stature affects children and adolescents, not only physically but also psychologically' Dr. Rasha Tarif, Head of the Paediatric Endocrinology Unit at Ain Shams University and Chair of European Society for Paediatric Endocrinology (ESPE) Education and Training Committee, said. 'Growth hormone plays a critical role in effective treatment plans, but ensuring its availability has been a challenge in recent years. This challenge is being addressed through ongoing efforts to secure sufficient quantities to ensure uninterrupted treatment until puberty is complete. Treatment continuity, along with proper follow-up with a specialized physician, is essential for achieving optimal results,' Dr. Tarif added. This new concentration is being made available, expanding treatment options in line with the latest global scientific standards. This will allow for a better patient response in the treatment journey by minimizing interruptions. Securing the reliable availability of this human growth hormone reinforces medical efforts to provide comprehensive care for children and reflects the Egyptian medical community's commitment to delivering advanced treatment solutions for patients in need. 'The Egyptian government, within the context of the Egypt Vision 2030, has shown strong commitment to reducing the prevalence of short stature among children, aiming to improve public health for current and future generations, and help build a healthier, more productive workforce, in line with the national vision for sustainable development,' Sameh Elbagoury, Sandoz Egypt Country Head, said. 'Our top priority at Sandoz is to develop affordable biosimilars for high-quality biologics and ensure that as many patients as possible have access to them. Introducing the 15 mg concentration of our well-established Omnitrope growth hormone allows us to help local authorities meet the increase in demand for growth hormones, reflecting the positive impact and notable success achieved by the Presidential Initiative for the Early Detection of Anaemia, Obesity and Short Stature,' Elbagoury added.
Daily News Egypt
2 days ago
- Daily News Egypt
Egypt's Health Minister reviews upgrades at Gustave Roussy Hospital
Egypt's Minister of Health and Population, Khaled Abdel Ghaffar, convened a meeting at the ministry's headquarters in the New Administrative Capital to review the quality of medical services provided at Gustave Roussy Hospital (formerly Al-Hermel). The meeting underscored the government's commitment to delivering high-quality healthcare to citizens, according to an official statement released on Saturday. During the meeting, Abdel Ghaffar stressed the importance of providing a supportive and comfortable environment for patients and their families. He directed the establishment of a dedicated unit to receive patient complaints and measure satisfaction, alongside streamlining medical and administrative procedures to enhance service delivery. The minister also called for strengthened coordination to ensure the continuous availability of essential medications and medical supplies. Abdel Ghaffar highlighted that over 12,000 state-funded treatment approvals were issued between 1 June and 18 July 2025. He further emphasised the need to accelerate the work of health insurance medical committees to speed up insurance approvals for patients. Ministry spokesperson Hossam Abdel Ghaffar announced the formation of a special task force to oversee the hospital's development plans and improvements to the work environment. This task force will implement regular reporting mechanisms to track performance and ensure sustained progress. The minister also instructed an increase in the number of highly trained medical and administrative staff and called for expanded cooperation with French experts from Gustave Roussy to train Egyptian teams in advanced treatment protocols. The Health Ministry reaffirmed its commitment to rigorous oversight of the hospital's operations, in coordination with the private sector, to guarantee equitable access to quality healthcare. It also highlighted its strategic partnership with Gustave Roussy International, aimed at improving patient outcomes and elevating standards of care.
